Drug development firm ImmuPharma said Monday that its key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor, has confirmed the effectiveness of a product known as Lupuzor peptide P140.
Partner CNRS released a statement saying that in a clinical trial involving 149 patients suffering with the Lupus, an autoimmune disease, the peptide was well tolerated by patients and led to a regression of the disease.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
New electric car grant worth up to £3,750 announced – how the scheme worksThe cost of a new electric car could be cut by up to £3,750. We explain how the new electric car grant works, and what cars are likely to be made cheaper.
-
The Treasury and the FCA want you to invest more – what the Leeds Reforms mean for your moneyAn overhaul of regulations and capital market rules by the Treasury and Financial Conduct Authority aim to boost retail investment. We explain what it means for you
